Trastuzumab biosimilar - EirGenix

Drug Profile

Trastuzumab biosimilar - EirGenix

Alternative Names: EG12014

Latest Information Update: 13 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EirGenix
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 May 2017 EG 12014 is available for licensing as of 12 May 2017. http://www.eirgenix.com/about.php
  • 04 May 2017 EirGenix completes a phase I trial in Breast cancer (In volunteers) in Europe
  • 04 May 2017 EirGenix plans a phase III global study for Breast cancer (Neoadjuvant therapy, Combination therapy) in USA and European Union countries (NCT03433313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top